---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059374"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T20:57:54.131126+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q3 net loss $108.4M; updates on RMC-6236, RMC-6291; EQRx close imminent

## Summary
- Q3 2023 net loss $108.4M vs $73.3M; revenue $0 vs $3.4M; R&D spend $107.7M (+55%).
- Cash $813.2M; updated FY2023 net loss guidance $385-$415M; cash runway into 2025.
- Promising clinical data for RMC-6236 (RAS MULTI) and RMC-6291 (RAS G12C); Phase 3 plans for NSCLC and PDAC in 2024.
- EQRx acquisition expected to close Nov 2023; all-stock deal, ~55M shares issued, adds ~$1.1B net cash (~$20/share issued).

## SEC filing metadata
- accession: 0000950170-23-059374
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017023059374/0000950170-23-059374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017023059374/rvmd-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059374
- JSON: https://secwatch.observer/filing/0000950170-23-059374.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059374.txt

## Key facts
- Earnings Releases
  Revolution Medicines, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 6, 2023, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000095017023059374/0000950170-23-059374-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.